Combined PARP14 Inhibition and PD-1 Blockade Promotes Cytotoxic T Cell Quiescence and Modulates Macrophage Polarization in Relapsed Melanoma

Researchers identified a robust PARP14 catalytic inhibitor gene signature and evaluated its association with patient survival. Using preclinical models and single-cell RNA sequencing, they investigated immune and tumor cell adaptations to PARP14 inhibition combined with programmed cell death 1 blockade.